Hudson Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 18, Cambridge, Massachuse...Phone Number
(919) 314-8385Website
www.hudsontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Hudson Therapeutics
Hudson Therapeutics, Inc. is dedicated to enhancing and restoring patients' lives by developing innovative drugs through a global clinical development process. As a subsidiary of Shaperon, Inc., the company focuses on strategic partnerships and patient-centric solutions. Their team of experts manages global clinical trials and works to license assets to leading pharmaceutical companies. Hudson Therapeutics aims to deliver transformative innovations that reach patients worldwide.Explore more
Popular SearchesHudson Therapeutics IncHudson TherapeuticsSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hudson Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Hudson Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Hudson Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Hudson Therapeutics launches new products
Funding: Get notified immidiatlly once Hudson Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Hudson Therapeutics
Earning: See what the market has to say on Hudson Therapeutics recently announced quarterly report
Check out if Hudson Therapeutics is spiking on competitors!
Hudson Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Hudson Therapeutics
Find 2 more new buyers
Compare Similar Companies to Hudson Therapeutics
Compare insights from companies similar to Hudson Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Hudson Therapeutics
<$5M
11-50
Private
-
2023
N/A
Company Profile Activity
Activity Insights
Hudson Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hudson Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hudson Therapeutics.
Hudson Therapeutics News & Media
Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for NuGel
DURHAM, N.C. & CAMBRIDGE, Mass. & SEOUL, South Korea--(BUSINESS WIRE)--Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its clinical trial for NuGel, a first-in-class inflammasome inhibitor designed to treat mild to moderate atopic dermatitis. A kickoff meeting was recently held in March in the United States, marking a significant milestone in the global clinical development of NuGel. The clinical trial will be conducted acHudson Therapeutics and Shaperon Report Positive Result of Phase 2B Part 1 for Nugel at JPM 2025
DURHAM, NC, UNITED STATES, January 24, 2025 /EINPresswire.com/ -- Hudson Therapeutics and Shaperon announced on January 24th that they engaged in in-depth discussions about out-licensing their next-generation atopic dermatitis treatment, NuGel, with …Hudson Therapeutics Announces Completion of Phase 2b Part 1 Clinical Trial for Nugel
SAN FRANCISCO, CA, UNITED STATES, January 16, 2025 /EINPresswire.com/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced the successful completion of Part 1 of the U.S. Phase 2b clinical trial for Nugel, the world’s first inflammatory …Hudson Therapeutics and Shaperon to Participate in Leading Major Global Biotech Conferences at the JPM Healthcare Week
DURHAM, NC, UNITED STATES, December 9, 2024 /EINPresswire.com/ -- Hudson Therapeutics, the US subsidiary of Shaperon, a leading innovator in therapeutic solutions, is excited to announce its participation in three major bio industry events during Bio …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hudson Therapeutics
Sign Up For FreeTo access detailed company insights
Hudson Therapeutics, Inc. is dedicated to enhancing and restoring patients' lives by developing innovative drugs through a global clinical development process. As a subsidiary of Shaperon, Inc., the company focuses on strategic partnerships and patient-centric solutions. Their team of experts manages global clinical trials and works to license asse... Read More
